Emergent BioSolutions (EBS) Capital Expenditures (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Capital Expenditures of $2.4 million for Q1 2026, down 33.33% year-over-year from $3.6 million in Q1 2025, and up 1300.0% quarter-over-quarter from -$200000.0 in Q4 2025.
Emergent BioSolutions (EBS) Capital Expenditures (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Capital Expenditures history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Capital Expenditures fell 33.33% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $400000.0 (down 98.28% YoY), while the FY2025 annual figure was $1.6 million, down 93.01% from the prior year.
- Capital Expenditures for Q1 2026 stood at $2.4 million, up from -$200000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $42.4 million in Q4 2023, with the low at -$82.8 million in Q4 2022.
- The 5-year median for Capital Expenditures is $3.6 million (2025), against an average of $5.2 million.
- Peak annual rise in Capital Expenditures reached 4112.5% in 2022, while the deepest fall reached 514.0% in 2022.
- Emergent BioSolutions' Capital Expenditures stood at -$82.8 million in 2022, then surged by 151.21% to $42.4 million in 2023, then plunged by 95.99% to $1.7 million in 2024, then tumbled by 111.76% to -$200000.0 in 2025, then surged by 1300.0% to $2.4 million in 2026.
- Business Quant data shows EBS's Capital Expenditures at $2.4 million in Q1 2026, -$200000.0 in Q4 2025, and -$4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.10 Mn |
| Jun 30, 2026 | 2.10 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Dec 31, 2025 | -200,000.00 |
| Dec 31, 2025 | -200,000.00 |
| Sep 30, 2025 | -4.70 Mn |
| Sep 30, 2025 | -4.70 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 3.60 Mn |
| Mar 31, 2025 | 3.60 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 5.80 Mn |
| Sep 30, 2024 | 5.80 Mn |
| Jun 30, 2024 | 12.10 Mn |
| Jun 30, 2024 | 12.10 Mn |
| Mar 31, 2024 | 3.30 Mn |
| Mar 31, 2024 | 3.30 Mn |